Get the Stockscreener App
0.3864
3.62%
0.0135
Generation Bio Co stock is traded at $0.3864, with a volume of 1.09M.
It is up +3.62% in the last 24 hours and down -1.18% over the past month.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
See More
Previous Close:
$0.3729
Open:
$0.3799
24h Volume:
1.09M
Relative Volume:
2.20
Market Cap:
$28.50M
Revenue:
-
Net Income/Loss:
$-126.61M
P/E Ratio:
-0.1971
EPS:
-1.96
Net Cash Flow:
$-60.14M
1W Performance:
+12.65%
1M Performance:
-1.18%
6M Performance:
-58.25%
1Y Performance:
-86.20%
1-Day Range:
$0.3742
$0.3995
1-Week Range:
$0.3223
$0.3995
52-Week Range:
$0.3004
$3.65
Generation Bio Co Stock (GBIO) Company Profile
Name
Generation Bio Co
Sector
Industry
Phone
857-529-5908
Address
301 BINNEY STREET, CAMBRIDGE
Compare GBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GBIO
Generation Bio Co
|
0.3864 | 28.50M | 0 | -126.61M | -60.14M | -1.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.85 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.94 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.24 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
250.30 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Generation Bio Co Stock (GBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-19-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Nov-08-22 | Initiated | Canaccord Genuity | Buy |
| Dec-14-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-08-21 | Initiated | JMP Securities | Mkt Outperform |
| Feb-24-21 | Initiated | William Blair | Outperform |
| Feb-18-21 | Initiated | Needham | Buy |
| Jul-07-20 | Initiated | Cowen | Outperform |
| Jul-07-20 | Initiated | JP Morgan | Overweight |
| Jul-07-20 | Initiated | Jefferies | Buy |
| Jul-07-20 | Initiated | Wedbush | Outperform |
View All
Generation Bio Co Stock (GBIO) Latest News
Post Bio announced on the 17th that it held a kick-off event for the open innovation project and sig.. - 매일경제
64x Bio Launches AAV Apex Suite to Power the Next Generation of Gene Therapy Manufacturing - Business Wire
Millennium Management LLC Makes New $97,000 Investment in Generation Bio Co. (NASDAQ:GBIO) - Defense World
Two Sigma Investments LP Sells 29,496 Shares of Generation Bio Co. (NASDAQ:GBIO) - Defense World
Squarepoint Ops LLC Takes Position in Generation Bio Co. (NASDAQ:GBIO) - Defense World
What Did We Note About Insider Trading At Generation Bio Co (NASDAQ: GBIO)? - Stocksregister
Generation Bio Elects Directors and Approves Key Proposals - TipRanks
Deutsche Bank AG Buys 160,822 Shares of Generation Bio Co. (NASDAQ:GBIO) - Defense World
Layoff Tracker: Keros Cuts 45% of Workforce Along With Pulmonary Hypertension Drug - BioSpace
Generation Bio to Present at the 2025 Jefferies Global Healthcare Conference | GBIO Stock News - GuruFocus
Generation Bio to Present at the 2025 Jefferies Global Healthcare Conference - The Manila Times
Generation Bio Reveals Latest T Cell Therapy Progress: CEO Set for Major Jefferies Healthcare Conference Spotlight - Stock Titan
Generation Bio’s SWOT analysis: t-cell targeting tech reshapes stock outlook By Investing.com - Investing.com South Africa
D. E. Shaw & Co. Inc. Has $366,000 Position in Generation Bio Co. (NASDAQ:GBIO) - Defense World
Generation Bio’s SWOT analysis: t-cell targeting tech reshapes stock outlook - Investing.com Nigeria
Pharma giant Eli Lilly eyes Houston for $5.9B biomanufacturing plant that could bring over 2,000 jobs - Houston Chronicle
Dimensional Fund Advisors LP Has $420,000 Stock Holdings in Generation Bio Co. (NASDAQ:GBIO) - Defense World
Wedbush Issues Negative Forecast for Generation Bio Earnings - Defense World
Needham & Company LLC Reaffirms “Buy” Rating for Generation Bio (NASDAQ:GBIO) - Defense World
Generation Bio Co (GBIO)’s Market Momentum: Closing Strong at 0.48, Down -6.25 - DWinneX
Generation Bio Co. Reports Reduced Losses and Increased Revenue - TipRanks
Where Generation Bio Stands With Analysts - Benzinga
Needham Reiterates Buy Rating for Generation Bio (GBIO) | GBIO Stock News - GuruFocus
Generation Bio Reports Recent Business Highlights and First Quarter 2025 Financial Results - The Manila Times
Generation Bio earnings beat by $0.08, revenue topped estimates - Investing.com
Generation Bio Co. (GBIO) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Metric Deep Dive: Understanding Generation Bio Co (GBIO) Through its Ratios - DWinneX
Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2024 Financial Results - ADVFN
Stately Bio Raises $12M Seed to Develop Next Generation Regenerative Medicines with ML-Powered Cellular Imaging Platform - WebWire
Renaissance Technologies LLC Has $1.02 Million Stock Position in Generation Bio Co. (NASDAQ:GBIO) - Defense World
Revolutionary Green Innovation: Braskem's Bio-Based Polyethylene Transforms Nonwovens Industry - Stock Titan
Generation Bio Co [GBIO] stock for 120,759 USD was acquired by Quinn Anthony G. - knoxdaily.com
GBIO’s Stock Market Puzzle: Piecing Together 2023’s Performance - investchronicle.com
Generation Bio Co (GBIO) presents a great opportunity, but the stock is slightly overvalued - uspostnews.com
Generation Bio Insiders Recover Some Losses, Which Stand At US$115k - simplywall.st
Generation Bio Co (NASDAQ: GBIO) Stock Is A Good Option To Consider - Stocksregister
Next-Generation Biomanufacturing Market Current Scenario with Future Trends Analysis to 2031 - openPR.com
Needham & Company LLC Reaffirms Buy Rating for Generation Bio (NASDAQ:GBIO) - Defense World
GBIO stock plunges to 52-week low of $0.34 amid market challenges - Investing.com Australia
GBIO stock plunges to 52-week low of $0.34 amid market challenges By Investing.com - Investing.com South Africa
LG Innotek, KAIST collaborate for next gen technology - 매일경제
Baker Hughes Co [BKR] Shares Rise 0.27 % on Wednesday - knoxdaily.com
Generation Bio stock hits 52-week low at $0.4 amid steep decline - Investing.com Australia
Generation Bio to Present at the Needham 24th Annual Virtual Healthcare Conference - The Manila Times
Generation Bio Co Stock (GBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Generation Bio Co Stock (GBIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Quinn Anthony G. | Director |
Jan 13 '25 |
Buy |
0.97 |
85,000 |
82,450 |
299,286 |
| Howze Yalonda | CHIEF LEGAL OFFICER |
Oct 15 '24 |
Option Exercise |
2.42 |
3,347 |
8,100 |
15,169 |
2.10%
1.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):